Literature DB >> 33595192

OPTN/SRTR 2019 Annual Data Report: Liver.

A J Kwong1, W R Kim1,2, J R Lake2,3, J M Smith2,4, D P Schladt2, M A Skeans2, S M Noreen5, J Foutz5, S E Booker5, M Cafarella5, J J Snyder2,6, A K Israni2,6,7, B L Kasiske2,7.   

Abstract

This year was notable for changes to exception points determined by the geographic median allocation Model for End-Stage Liver Disease (MELD) and implementation of the National Liver Review Board, which took place on May 14, 2019. The national acuity circle liver distribution policy was also implemented but reverted to donor service area- and region-based boundaries after 1 week. In 2019, growth continued in the number of new waiting list registrations (12,767) and transplants performed (8,896), including living-donor transplants (524). Compared with 2018, living-donor liver transplants increased 31%. Women continued to have a lower deceased-donor transplant rate and a higher pretransplant mortality rate than men. The median waiting time for candidates with a MELD of 15-34 decreased, while the number of transplants performed for patients with exception points decreased. These changes may have been related to the policy changes that took effect in May 2019, which increased waiting list priority for candidates without exception status. Hepatitis C continued to decline as an indication for liver transplant, as the proportion of liver transplant recipients with alcohol-related liver disease and clinical profiles consistent with non-alcoholic steatohepatitis increased. Graft and patient survival have improved despite changing recipient demographics including older age, higher MELD, and higher prevalence of obesity and diabetes. .

Entities:  

Keywords:  Liver transplant; allocation; distribution; waiting list

Mesh:

Year:  2021        PMID: 33595192     DOI: 10.1111/ajt.16494

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  42 in total

1.  Induction Therapy and Therapeutic Antibodies.

Authors:  Andriana Nikolova; Jignesh K Patel
Journal:  Handb Exp Pharmacol       Date:  2022

Review 2.  Malnutrition in Biliary Atresia: Assessment, Management, and Outcomes.

Authors:  Julia M Boster; Amy G Feldman; Cara L Mack; Ronald J Sokol; Shikha S Sundaram
Journal:  Liver Transpl       Date:  2021-11-10       Impact factor: 5.799

3.  The use of normothermic machine perfusion to rescue liver allografts from expanded criteria donors.

Authors:  Aurelio Seidita; Rosalia Longo; Fabrizio Di Francesco; Alessandro Tropea; Sergio Calamia; Giovanna Panarello; Marco Barbara; Salvatore Gruttadauria
Journal:  Updates Surg       Date:  2021-09-20

Review 4.  Outcomes of Children with Fetal and Lactation Immunosuppression Exposure Born to Female Transplant Recipients.

Authors:  Cameron J McKinzie; Jillian P Casale; Jack C Guerci; Alyson Prom; Christina T Doligalski
Journal:  Paediatr Drugs       Date:  2022-07-23       Impact factor: 3.930

Review 5.  The care of donors and recipients in adult living donor liver transplantation.

Authors:  A Hendrickse; J Ko; T Sakai
Journal:  BJA Educ       Date:  2022-08-23

6.  Primary Liver Transplantation vs. Transplant after Kasai Portoenterostomy for Infants with Biliary Atresia.

Authors:  Caroline P Lemoine; John P LeShock; Katherine A Brandt; Riccardo Superina
Journal:  J Clin Med       Date:  2022-05-26       Impact factor: 4.964

7.  Proton Beam Therapy for Multifocal Hepatocellular Carcinoma (HCC) Showing Complete Response in Pathological Anatomy After Liver Transplantation.

Authors:  Yinuo Li; Shosei Shimizu; Masashi Mizumoto; Takashi Iizumi; Haruko Numajiri; Hirokazu Makishima; Gong Li; Hideyuki Sakurai
Journal:  Cureus       Date:  2022-06-08

8.  The volume-outcomes relationship in donation after circulatory death liver transplantation.

Authors:  Aaron M Delman; Kevin M Turner; Allison M Ammann; Emily Schepers; Dennis M Vaysburg; Alex R Cortez; Robert M Van Haren; Greg C Wilson; Shimul A Shah; Ralph C Quillin
Journal:  Clin Transplant       Date:  2022-04-25       Impact factor: 3.456

Review 9.  Therapeutic Potential of HNF4α in End-stage Liver Disease.

Authors:  Ricardo Diaz-Aragon; Michael C Coard; Sriram Amirneni; Lanuza Faccioli; Nils Haep; Michelle R Malizio; Takashi Motomura; Zehra N Kocas-Kilicarslan; Alina Ostrowska; Rodrigo M Florentino; Carla Frau
Journal:  Organogenesis       Date:  2021-10-02       Impact factor: 2.316

10.  Correcting the sex disparity in MELD-Na.

Authors:  Nicholas L Wood; Douglas VanDerwerken; Dorry L Segev; Sommer E Gentry
Journal:  Am J Transplant       Date:  2021-07-12       Impact factor: 9.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.